Cargando…
Evaluation of off-label rapamycin use to promote healthspan in 333 adults
Rapamycin (sirolimus) is an FDA-approved drug with immune-modulating and growth-inhibitory properties. Preclinical studies have shown that rapamycin extends lifespan and healthspan metrics in yeast, invertebrates, and rodents. Several physicians are now prescribing rapamycin off-label as a preventat...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187519/ https://www.ncbi.nlm.nih.gov/pubmed/37191826 http://dx.doi.org/10.1007/s11357-023-00818-1 |
_version_ | 1785145850396147712 |
---|---|
author | Kaeberlein, Tammi L. Green, Alan S. Haddad, George Hudson, Johnny Isman, Anar Nyquist, Andy Rosen, Bradley S. Suh, Yousin Zalzala, Sajad Zhang, Xingyu Blagosklonny, Mikhail V. An, Jonathan Y. Kaeberlein, Matt |
author_facet | Kaeberlein, Tammi L. Green, Alan S. Haddad, George Hudson, Johnny Isman, Anar Nyquist, Andy Rosen, Bradley S. Suh, Yousin Zalzala, Sajad Zhang, Xingyu Blagosklonny, Mikhail V. An, Jonathan Y. Kaeberlein, Matt |
author_sort | Kaeberlein, Tammi L. |
collection | PubMed |
description | Rapamycin (sirolimus) is an FDA-approved drug with immune-modulating and growth-inhibitory properties. Preclinical studies have shown that rapamycin extends lifespan and healthspan metrics in yeast, invertebrates, and rodents. Several physicians are now prescribing rapamycin off-label as a preventative therapy to maintain healthspan. Thus far, however, there is limited data available on side effects or efficacy associated with use of rapamycin in this context. To begin to address this gap in knowledge, we collected data from 333 adults with a history of off-label use of rapamycin by survey. Similar data were also collected from 172 adults who had never used rapamycin. Here, we describe the general characteristics of a patient cohort using off-label rapamycin and present initial evidence that rapamycin can be used safely in adults of normal health status. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11357-023-00818-1. |
format | Online Article Text |
id | pubmed-10187519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-101875192023-11-15 Evaluation of off-label rapamycin use to promote healthspan in 333 adults Kaeberlein, Tammi L. Green, Alan S. Haddad, George Hudson, Johnny Isman, Anar Nyquist, Andy Rosen, Bradley S. Suh, Yousin Zalzala, Sajad Zhang, Xingyu Blagosklonny, Mikhail V. An, Jonathan Y. Kaeberlein, Matt GeroScience Article Rapamycin (sirolimus) is an FDA-approved drug with immune-modulating and growth-inhibitory properties. Preclinical studies have shown that rapamycin extends lifespan and healthspan metrics in yeast, invertebrates, and rodents. Several physicians are now prescribing rapamycin off-label as a preventative therapy to maintain healthspan. Thus far, however, there is limited data available on side effects or efficacy associated with use of rapamycin in this context. To begin to address this gap in knowledge, we collected data from 333 adults with a history of off-label use of rapamycin by survey. Similar data were also collected from 172 adults who had never used rapamycin. Here, we describe the general characteristics of a patient cohort using off-label rapamycin and present initial evidence that rapamycin can be used safely in adults of normal health status. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11357-023-00818-1. Springer International Publishing 2023-05-16 /pmc/articles/PMC10187519/ /pubmed/37191826 http://dx.doi.org/10.1007/s11357-023-00818-1 Text en © The Author(s), under exclusive licence to American Aging Association 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
spellingShingle | Article Kaeberlein, Tammi L. Green, Alan S. Haddad, George Hudson, Johnny Isman, Anar Nyquist, Andy Rosen, Bradley S. Suh, Yousin Zalzala, Sajad Zhang, Xingyu Blagosklonny, Mikhail V. An, Jonathan Y. Kaeberlein, Matt Evaluation of off-label rapamycin use to promote healthspan in 333 adults |
title | Evaluation of off-label rapamycin use to promote healthspan in 333 adults |
title_full | Evaluation of off-label rapamycin use to promote healthspan in 333 adults |
title_fullStr | Evaluation of off-label rapamycin use to promote healthspan in 333 adults |
title_full_unstemmed | Evaluation of off-label rapamycin use to promote healthspan in 333 adults |
title_short | Evaluation of off-label rapamycin use to promote healthspan in 333 adults |
title_sort | evaluation of off-label rapamycin use to promote healthspan in 333 adults |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10187519/ https://www.ncbi.nlm.nih.gov/pubmed/37191826 http://dx.doi.org/10.1007/s11357-023-00818-1 |
work_keys_str_mv | AT kaeberleintammil evaluationofofflabelrapamycinusetopromotehealthspanin333adults AT greenalans evaluationofofflabelrapamycinusetopromotehealthspanin333adults AT haddadgeorge evaluationofofflabelrapamycinusetopromotehealthspanin333adults AT hudsonjohnny evaluationofofflabelrapamycinusetopromotehealthspanin333adults AT ismananar evaluationofofflabelrapamycinusetopromotehealthspanin333adults AT nyquistandy evaluationofofflabelrapamycinusetopromotehealthspanin333adults AT rosenbradleys evaluationofofflabelrapamycinusetopromotehealthspanin333adults AT suhyousin evaluationofofflabelrapamycinusetopromotehealthspanin333adults AT zalzalasajad evaluationofofflabelrapamycinusetopromotehealthspanin333adults AT zhangxingyu evaluationofofflabelrapamycinusetopromotehealthspanin333adults AT blagosklonnymikhailv evaluationofofflabelrapamycinusetopromotehealthspanin333adults AT anjonathany evaluationofofflabelrapamycinusetopromotehealthspanin333adults AT kaeberleinmatt evaluationofofflabelrapamycinusetopromotehealthspanin333adults |